STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACUR
  4. [8-K] ACURA PHARMACEUTICALS, INC Reports Material Event

Acura Pharmaceuticals (OTC: ACUR) takes $200K loan and warns on survival

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Acura Pharmaceuticals, Inc. received a new $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026 under its existing secured promissory note, bringing total principal owed to $10,894,279 plus about $1,200,000 of accrued interest as of that date.

The note bears 5.25% annual interest, with 7.5% on overdue amounts and typical events of default. Management states the funding was used for day‑to‑day operations and warns that without additional financing by mid‑August 2026 it may have to scale back, furlough or lay off employees, terminate operations and/or seek bankruptcy protection, which it states could result in a complete loss of shareholder value. The company also cites obligations to obtain FDA acceptance of an NDA for LTX‑03 and to repay the note and interest by December 31, 2026, alongside extensive regulatory and development risks for its LIMITx and Impede technologies.

Positive

  • None.

Negative

  • The company warns that without additional financing by mid-August 2026, it may need to scale back or cease operations and/or seek bankruptcy protection, which it states could result in a complete loss of shareholder value.
  • Debt to Abuse Deterrent Pharma, LLC has grown to $10,894,279 in principal plus about $1,200,000 of accrued interest at 5.25%, concentrated in a single secured note that the company expects to repay by December 31, 2026.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
New loan amount $200,000 Loan from Abuse Deterrent Pharma, LLC on July 17, 2026
Total principal balance $10,894,279 Principal outstanding under secured promissory note as of July 17, 2026
Accrued interest approximately $1,200,000 Accrued interest on the note as of July 17, 2026
Base interest rate 5.25% per annum Standard interest rate on the secured promissory note
Default interest rate 7.5% per annum Interest rate applied to overdue amounts following non-payment
Note payoff date December 31, 2026 Referenced date to repay secured promissory note and accrued interest
Financing deadline for operations mid-August 2026 Company cites need for additional financing by this time to avoid cutbacks or bankruptcy
Amended, Consolidated and Restated Secured Promissory Note financial
"Amended, Consolidated and Restated Secured Promissory Note with Abuse Deterrent Pharma, LLC"
Events of default financial
"The Events of default under the Note include, among other items, bankruptcy events"
Events of default are specific breaches or failures listed in a loan, bond, or credit agreement that give lenders the right to act, such as demanding immediate repayment, raising interest rates, or taking secured assets. They matter to investors because triggering one is like setting off a financial alarm: it raises the chance of foreclosure, restructuring, or bankruptcy and can sharply reduce the value of a company’s stock or bonds and increase borrowing costs.
New Drug Application regulatory
"whether we can successfully submit a New Drug Application for LTX-03"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
LIMITx Technology technical
"including the development of our products utilizing our LIMITx™ and Impede® technologies"
paragraph IV patent infringement litigation regulatory
"our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What new financing did Acura Pharmaceuticals (ACUR) receive in July 2026?
Acura Pharmaceuticals received a $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026. This funding was applied to day-to-day operating activities and increased the outstanding balance under the secured promissory note documented between the two parties.

How much does Acura Pharmaceuticals (ACUR) now owe under its secured promissory note?
As of July 17, 2026, Acura reports principal of $10,894,279 and accrued interest of about $1,200,000 under the note. These amounts reflect the original $2,319,279 promissory note plus a series of subsequent loans from Abuse Deterrent Pharma.

What interest rates apply to Acura Pharmaceuticals’ (ACUR) note with Abuse Deterrent Pharma?
The secured promissory note bears interest at 5.25% per annum under normal conditions. If any amount is overdue after applicable grace periods, that overdue amount accrues interest at 7.5% per annum until paid in full, following an event of non-payment.

What going-concern risks does Acura Pharmaceuticals (ACUR) highlight regarding its financing?
Acura states that without additional financing by mid-August 2026, it may need to scale back operations, furlough or lay off employees, terminate operations and/or seek bankruptcy. It further notes this scenario could lead to a complete loss of shareholder value.

When must Acura Pharmaceuticals (ACUR) repay its secured promissory note to Abuse Deterrent Pharma?
Acura references an obligation to repay the secured promissory note and accrued interest to Abuse Deterrent Pharma by December 31, 2026. It also cites that same date as the current deadline to obtain FDA acceptance of an NDA for its LTX‑03 product candidate.

How does the Abuse Deterrent Pharma financing relate to Acura Pharmaceuticals’ (ACUR) product pipeline?
The company notes its ability to obtain funding from Abuse Deterrent Pharma, LLC or others is important to support products based on its LIMITx and Impede technologies, including the LTX‑03 hydrocodone/acetaminophen candidate, for which FDA acceptance of an NDA is targeted by December 31, 2026.
false 0000786947 0000786947 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

 

Date of Report (Date of earliest event reported): July 17, 2026

 

 

 

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as specified in its Charter)

 

 

  

New York 1-10113 11-0853640
(State or other jurisdiction of
incorporation or organization)		 (Commission File Number) (I.R.S. Employer
Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip code)

 

(847) 705-7709

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share ACUR OTC Market – OTC Expert Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01 - Entry into a Material Definitive Agreement.

 

On July 17, 2026, we received a $200,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $10,894,279 with accrued interest of approximately $1,200,000 as of July 17, 2026 and bears interest at 5.25% (“Note”). The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full.

 

The funding provided by AD Pharma was used to meet day-to-day operation activity. There can be no assurance we will be successful in receiving additional financing. In the absence of the receipt of additional financing by mid-August 2026, we will be required to scale back our operations, including the furlough and lay-off of employees, or to terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operation.

 

The inclusion of a description of the Note under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Note is a material agreement not made, or deemed not to be made, in the ordinary course of our business.

 

Item 2.01 – Completion of Acquisition or Disposition of Assets

 

The contents of all Items 1.01 are incorporated herein by reference.

 

Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The contents of all Items 1.01 are incorporated herein by reference.

 

Acura Forward-Looking Statements

 

Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and these forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

 

Forward-looking statements may include, but are not limited to:

 

●whether the FDA will agree with or accept the results of our studies for our product candidates;
●the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;
●whether we can successfully submit a New Drug Application for LTX-03, request a priority review and whether such filings and requests will be accepted by the FDA;
●our ability to obtain funding from Abuse Deterrent Pharma, LLC or other parties for our continuing operations, including the development of our products utilizing our LIMITx™ and Impede® technologies;
●whether we can renegotiate the date by which we are required to obtain FDA acceptance, currently December 31, 2026, for an NDA for LTX-03 by our agreement with Abuse Deterrent Pharma, LLC on which we depend to finance operations;
●whether we can renegotiate the date by which we are required to pay off the secured promissory note and accrued interest to Abuse Deterrent Pharma, LLC, currently December 31, 2026, 2026;
●whether our licensing partners will develop any additional products and utilize Acura for such development;
●the expected results of clinical studies relating to LTX-03, a LIMITx hydrocodone bitartrate and acetaminophen combination product, or any successor product candidate, the date by which such studies will be complete and the results will be available and whether LTX-03 will ultimately receive FDA approval;
●our business could be adversely affected by health epidemics in regions where third parties for which we rely, as in CROs or CMOs, have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely;

 

2

 

 

●whether LIMITx will retard the release of opioid active ingredients as dose levels increase;
●whether the extent to which products formulated with the LIMITx Technology reduce respiratory depression will be determined sufficient by the FDA to support approval or labelling describing safety features;
●our and our licensee’s ability to successfully launch and commercialize our products and technologies;
●the results and timing of our development of our LIMITx Technology, including, but not limited to, the submission of a NDA and/or FDA filing acceptance;
●our or our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
●the market acceptance of, timing of commercial launch and competitive environment for any of our products;
●expectations regarding potential market share for our products;
●our ability to develop and enter into additional license agreements for our product candidates using our technologies;
●our exposure to product liability and other lawsuits in connection with the commercialization of our products;
●the increasing cost of insurance and the availability of product liability insurance coverage;
●the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
●the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
●the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
●changes in regulatory requirements;
●adverse safety findings relating to our commercialized products or product candidates in development;
●whether the FDA will agree with our analysis of our clinical and laboratory studies;
●whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and
●whether our product candidates will ultimately perform as intended in commercial settings.

 

In some cases, you can identify forward-looking statements by terms such as “aim”, "anticipate", "believe", "could", "design", "estimate", "expect", "forecast", "goal", "guidance", "imply", “indicate”, "intend", "may", "objective", "opportunity", "outlook", "plan", "position", "potential", "predict", "project", "prospective", "pursue", "seek", "should", "strategy", "target", "would", "will", and other words of similar meaning, expressions, derivations of such words and the use of future dates intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in Acura’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and in other filings Acura makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date of the Current Report and are based on the Company’s current beliefs, assumptions, and expectations. While Acura may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this Current Report whether as a result of new information or future events, except as may be required by applicable law.

 

Item 9.01 - Financial Statements and Exhibits

  

Exhibit Number Description
99.1 Amended Loan Schedule dated July 20, 2026 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with Abuse Deterrent Pharma, LLC
104 Cover Page Interactive Data File (embedded within Inline XBRL document)

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.
   
  By: /s/ Robert A. Seiser
    Robert A. Seiser
    Senior Vice President & Chief Financial Officer

 

Date:     July 24, 2026

 

4

 

Exhibit 99.1

 

Amended Loan Schedule to Secured Promissory Note dated November 10, 2022

between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC

 

   Date   Principal   Aggregated
Principal		 
Original Secured Promissory Note   11/10/2022   $2,319,279   $2,319,279 
Additional Loans to be included:               
Loans #1 dated 12/22/2022 through Loans #50 dated 12/31/2025       $7,075,000   $9,394,279 
Loan #51   1/02/2026   $100,000   $9,494,279 
Loan #52   1/16/2026   $100,000   $9,594,279 
Loan #53   2/06/2026   $100,000   $9,694,279 
Loan #54   2/13/2026   $100,000   $9,794,279 
Loan #55   3/09/2026   $100,000   $9,894,279 
Loan #56   3/30/2026   $100,000   $9,994,279 
Loan #57   4/03/2026   $100,000   $10,094,279 
Loan #58   4/20/2026   $100,000   $10,194,279 
Loan #59   5/05/2026   $100,000   $10,294,279 
Loan #60   5/15/2026   $100,000   $10,394,279 
Loan #61   5/29/2026   $100,000   $10,494,279 
Loan #62   6/24/2026   $200,000   $10,694,279 
Loan #63   7/17/2026   $200,000   $10,894,279 

 

ACURA PHARMACEUTICALS, INC.  
           
By: /s/ Robert A. Seiser                      
Robert A. Seiser  
Senior Vice President & CFO  
Date: July 20, 2026  

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents